Literature DB >> 26399685

Epigenetic alteration of the purinergic type 7 receptor in salivary epithelial cells.

Yong-Hwan Shin1, Minkyoung Kim1, Nahyun Kim1, Seul-Ki Choi1, Eun Namkoong1, Se-Young Choi1, Jong-Ho Lee2, Seunghee Cha3, Kyungpyo Park4.   

Abstract

Purinergic receptors, particularly type 7 (P2RX7), are involved in apoptotic cell death. However, the expression and function of P2RX7 are suppressed in HSG cells. In the present study, we explored whether P2RX7 function is regulated by epigenetic alteration of the receptors in two different cell lines, HSG cells derived from human submandibular ducts, and A253 cells, originated from human submandibular carcinoma. We discovered that HSG cells expressed all subtypes of purinergic receptors, excluding P2RX7, at the mRNA level. However, treatment of the cells with 5-Aza-CdR, a DNA demethylating agent, increased the mRNA expression levels of P2RX7 in a time-dependent manner. Furthermore, 5-Aza-CdR completely rescued the calcium response induced by P2RX7 agonist BzATP, a response that was absent in untreated HSG cells. In contrast, A253 cells showed a moderate methylation pattern in the P2RX7 CpG island. Most CG pairs from the first to the 21st were methylated in untreated HSG cells, but 5-Aza-CdR-treatment partially demethylated the methylated CG pairs. We obtained similar results when investigated human tissues; the CG pairs in the P2RX7 CpG islands showed hypermethylation and hypomethylation patterns in human normal and cancer tissues, respectively. Our results suggest that the expression level and function of P2RX7 are regulated by DNA methylation in epithelial cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Aza-CdR; DNA methylation; Hypermethylation; Hypomethylation; Purinergic receptor; Salivary glands

Mesh:

Substances:

Year:  2015        PMID: 26399685      PMCID: PMC4775087          DOI: 10.1016/j.bbrc.2015.09.095

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Mammalian X chromosome inactivation.

Authors:  R Jaenisch; C Beard; J Lee; Y Marahrens; B Panning
Journal:  Novartis Found Symp       Date:  1998

2.  DNA methylation affects the formation of active chromatin.

Authors:  I Keshet; J Lieman-Hurwitz; H Cedar
Journal:  Cell       Date:  1986-02-28       Impact factor: 41.582

Review 3.  Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

Authors:  Richard L Momparler
Journal:  Semin Oncol       Date:  2005-10       Impact factor: 4.929

4.  Expression of P2X7 receptor increases in vivo tumor growth.

Authors:  Elena Adinolfi; Lizzia Raffaghello; Anna Lisa Giuliani; Luigi Cavazzini; Marina Capece; Paola Chiozzi; Giovanna Bianchi; Guido Kroemer; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

5.  Salivary gland nucleotide receptors: evidence for functional expression of both P2X and P2Y subtypes.

Authors:  J T Turner; G A Weisman; L A Landon; M Park; J M Camden
Journal:  Eur J Morphol       Date:  1998-08

6.  Capsaicin regulates the NF-κB pathway in salivary gland inflammation.

Authors:  Y-H Shin; E Namkoong; S Choi; J-S Bae; M Jin; S-M Hwang; R Arote; S-Y Choi; K Park
Journal:  J Dent Res       Date:  2013-04-19       Impact factor: 6.116

7.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

8.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

9.  P2X7 Receptor Function in Bone-Related Cancer.

Authors:  Elena Adinolfi; Francesca Amoroso; Anna Lisa Giuliani
Journal:  J Osteoporos       Date:  2012-08-16

10.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more
  6 in total

Review 1.  ATP-gated P2X7 receptor as a potential target for prostate cancer.

Authors:  Cuicui Qiao; Yiqing Tang; Qianqian Li; Xiaodi Zhu; Xiaoxiang Peng; Ronglan Zhao
Journal:  Hum Cell       Date:  2022-06-03       Impact factor: 4.374

2.  Role of epigenetics in modulation of immune response at the junction of host-pathogen interaction and danger molecule signaling.

Authors:  Ana Carolina Morandini; Carlos F Santos; Özlem Yilmaz
Journal:  Pathog Dis       Date:  2016-08-18       Impact factor: 3.166

Review 3.  Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.

Authors:  Brianne Cruickshank; Michael Giacomantonio; Paola Marcato; Sherri McFarland; Jonathan Pol; Shashi Gujar
Journal:  Front Immunol       Date:  2018-04-03       Impact factor: 7.561

4.  P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer.

Authors:  Ju Young Bae; Sang-Woo Lee; Yong-Hwan Shin; Jong-Ho Lee; Jeong Won Jahng; Kyungpyo Park
Journal:  Oncotarget       Date:  2017-07-25

5.  Reduced P2X receptor levels are associated with antidepressant effect in the learned helplessness model.

Authors:  Deidiane Elisa Ribeiro; Plinio C Casarotto; Laura Staquini; Maria Augusta Pinto E Silva; Caroline Biojone; Gregers Wegener; Samia Joca
Journal:  PeerJ       Date:  2019-10-21       Impact factor: 2.984

6.  Epigenetic Modification of CFTR in Head and Neck Cancer.

Authors:  Yonghwan Shin; Minkyoung Kim; Jonghwa Won; Junchul Kim; Seog Bae Oh; Jong-Ho Lee; Kyungpyo Park
Journal:  J Clin Med       Date:  2020-03-09       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.